Reyon Pharmaceutical Co Ltd (102460) — Cash Flow Quality Index
Reyon Pharmaceutical Co Ltd (102460) has a Cash Flow Quality Index of 11.17x as of March 2025. Operating cash flow of ₩2.41 Billion exceeds net income of ₩216.09 Million, indicating high earnings quality where cash backs reported profits. Explore Reyon Pharmaceutical Co Ltd debt service capacity to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Reyon Pharmaceutical Co Ltd Cash Flow Quality Index (2008–2024)
Historical Cash Flow Quality Index for Reyon Pharmaceutical Co Ltd across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see how efficiently does Reyon Pharmaceutical Co Ltd generate cash.
Annual Cash Flow Quality Index for Reyon Pharmaceutical Co Ltd (2008–2024)
Year-by-year earnings quality comparison for Reyon Pharmaceutical Co Ltd.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -0.35x | ₩-1.44 Billion | ₩4.15 Billion | ▼ -114.3% |
| 2023 | 2.41x | ₩8.65 Billion | ₩3.58 Billion | ▲ +105.5% |
| 2022 | 1.17x | ₩8.73 Billion | ₩7.43 Billion | ▼ -44.4% |
| 2021 | 2.11x | ₩11.68 Billion | ₩5.54 Billion | ▲ +76.4% |
| 2020 | 1.20x | ₩4.60 Billion | ₩3.84 Billion | ▲ +158.3% |
| 2019 | -2.05x | ₩-12.18 Billion | ₩5.94 Billion | ▼ -124.1% |
| 2018 | 8.53x | ₩11.45 Billion | ₩1.34 Billion | ▲ +555.4% |
| 2017 | 1.30x | ₩16.76 Billion | ₩12.89 Billion | ▲ +47.0% |
| 2016 | 0.89x | ₩9.47 Billion | ₩10.70 Billion | ▼ -39.0% |
| 2012 | 1.45x | ₩24.65 Billion | ₩16.99 Billion | ▲ +87.0% |
| 2011 | 0.78x | ₩15.34 Billion | ₩19.78 Billion | ▲ +45.5% |
| 2009 | 0.53x | ₩8.68 Billion | ₩16.29 Billion | ▼ -30.2% |
| 2008 | 0.76x | ₩5.99 Billion | ₩7.84 Billion | — |